Connor Clark & Lunn Investment Management Ltd. lessened its holdings in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 17.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 202,903 shares of the medical equipment provider’s stock after selling 42,108 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.52% of Lantheus worth $5,742,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its holdings in shares of Lantheus by 41.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,034,497 shares of the medical equipment provider’s stock valued at $28,584,000 after acquiring an additional 304,537 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its stake in shares of Lantheus by 5.3% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 12,522 shares of the medical equipment provider’s stock valued at $354,000 after purchasing an additional 630 shares during the last quarter. Hillsdale Investment Management Inc. lifted its stake in shares of Lantheus by 28.2% in the 2nd quarter. Hillsdale Investment Management Inc. now owns 132,800 shares of the medical equipment provider’s stock valued at $3,758,000 after purchasing an additional 29,200 shares during the last quarter. Swiss National Bank lifted its stake in shares of Lantheus by 2.3% in the 2nd quarter. Swiss National Bank now owns 71,700 shares of the medical equipment provider’s stock valued at $2,029,000 after purchasing an additional 1,600 shares during the last quarter. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Lantheus in the 2nd quarter valued at $578,000. 95.73% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have weighed in on LNTH. Zacks Investment Research lowered shares of Lantheus from a “hold” rating to a “sell” rating in a research report on Friday, August 2nd. BidaskClub raised shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Friday. ValuEngine lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, CJS Securities raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $29.00.
In related news, SVP Michael P. Duffy sold 5,604 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $20.60, for a total transaction of $115,442.40. Following the completion of the transaction, the senior vice president now owns 138,890 shares in the company, valued at $2,861,134. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Brian A. Markison sold 5,000 shares of the stock in a transaction dated Wednesday, June 19th. The shares were sold at an average price of $27.40, for a total transaction of $137,000.00. Following the transaction, the director now owns 42,467 shares of the company’s stock, valued at approximately $1,163,595.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 111,552 shares of company stock valued at $2,911,266. Company insiders own 2.60% of the company’s stock.
Shares of Lantheus stock opened at $24.03 on Friday. Lantheus Holdings Inc has a 1-year low of $12.59 and a 1-year high of $29.80. The company has a current ratio of 2.62, a quick ratio of 2.01 and a debt-to-equity ratio of 2.05. The firm’s 50-day moving average price is $22.62 and its two-hundred day moving average price is $24.74. The stock has a market capitalization of $869.96 million, a price-to-earnings ratio of 25.56, a P/E/G ratio of 1.87 and a beta of 1.50.
Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $0.27 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.27. Lantheus had a net margin of 11.20% and a return on equity of 51.08%. The business had revenue of $85.70 million for the quarter, compared to analysts’ expectations of $88.72 million. During the same period in the prior year, the firm earned $0.25 earnings per share. Lantheus’s revenue was up .1% compared to the same quarter last year. As a group, equities research analysts predict that Lantheus Holdings Inc will post 1 EPS for the current year.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Recommended Story: What are municipal bonds?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.